News


  • 02 June 2017

    NovaDigm Therapeutics Awarded $6 Million by U.S. Department of Defense to Conduct a Phase 2a Staphylococcus aureus Vaccine Trial

    NovaDigm Therapeutics Awarded $6 Million by U.S. Department of Defense to Conduct a Phase 2a Staphylococcus aureus Vaccine Trial

    NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced awards totaling $6 million from the U.S. Department of Defense to conduct a clinical study of NDV-3A in military personnel at high risk for skin and soft tissue infections due to Staphylococcus aureus (“S. aureus”), including methicillin-resistant S. aureus (MRSA). NovaDigm will collaborate with the Uniformed Services University of the Health Sciences (USU) on the execution of the Phase 2a study among U.S. Army Infantry trainees at Fort Benning, GA.

  • 30 May 2017

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

  • 29 May 2017

    NovaMedica appoints Alexander Kuzin as General Director (CEO)

    NovaMedica appoints Alexander Kuzin as General Director (CEO)

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the appointment of Alexander Kuzin to the post of General Director (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017.

  • 24 May 2017

    Syndax Prices Public Offering of Common Stock

    Syndax Prices Public Offering of Common Stock

    Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $49.7 million. The offering is expected to close on May 31, 2017, subject to customary closing conditions.

  • 23 May 2017

    Syndax Announces Proposed Public Offering of Common Stock

    Syndax Announces Proposed Public Offering of Common Stock

    Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.

  • 17 May 2017

    Celtaxsys announces full enrollment of its landmark EMPIRE-CF phase 2b clinical trial assessing the potential of novel anti-inflammatory investigational therapy, oral acebilustat, to preserve lung function in CF patients

    Celtaxsys announces full enrollment of its landmark EMPIRE-CF phase 2b clinical trial assessing the potential of novel anti-inflammatory investigational therapy, oral acebilustat, to preserve lung function in CF patients

    Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare pulmonary diseases, announced today the full enrollment of its phase 2b clinical trial testing its flagship anti-inflammatory drug candidate, once-daily oral acebilustat, in adult CF patients (NCT02443688). The study is investigating the potential of acebilustat to reduce lung inflammation and preserve lung function over the course of 48 weeks in CF patients at a high risk for rapid lung function decline. 

  • 16 May 2017

    Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies

    Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported that the ENCORE 601 non-small cell lung cancer (NSCLC) cohort enrolling patients with disease progression on or after PD-1 therapy (programmed death receptor-1 (PD-1) and/or programmed death ligand 1, (PD-L1)) has met the pre-specified objective response threshold to advance into the second stage of the Phase 2 trial, and will re-open enrollment immediately.

  • 08 May 2017

    Epic Sciences and collaborators publish study on new blood test showing expression of PD-L1 on circulating cells is associated with worse outcomes in lung cancer patients not treated with PD-1 inhibitors

    Epic Sciences and collaborators publish study on new blood test showing expression of PD-L1 on circulating cells is associated with worse outcomes in lung cancer patients not treated with PD-1 inhibitors

    Investigators from Yale, USC, UC San Diego, and Epic Sciences published findings in Cancer Epidemiology, Biomarkers & Prevention, showing that the presence of PD-L1 protein on circulating cells from newly diagnosed lung cancer patients is prognostic of poor survival when patients are treated with standard of care therapeutics not including PD-1 inhibitors.

  • 24 April 2017

    Epic Sciences Announces Completion of $40 Million Series D Financing

    Epic Sciences Announces Completion of $40 Million Series D Financing

    Epic Sciences (Epic) announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures also participated in the financing. Epic is developing a portfolio of blood-based tests that predict drug response in cancer and recently partnered with Genomic Health to commercialize the OncotypeDx® AR-V7 Nucleus Detect™ test to leverage Genomic Health's world-class commercial channel and enterprise systems.

  • 21 April 2017

    NovaMedica and Pfizer won the Platinum Ounce award in the nomination Deal of the Year

    NovaMedica and Pfizer won the Platinum Ounce award in the nomination Deal of the Year

    NovaMedica, Russian pharmaceutical company, and Pfizer, one of the leaders of the world biopharmaceutical industry, were recognized as winners of the open professional contest “Platinum Ounce” in the nomination “Deal of the Year” for the long-term partnership agreement which envisages construction of a high-technology pharmaceutical production facility and localization of more than 30 life-saving and essential drugs in Russia.